Christopher Wraight

Christopher Wraight is an experienced executive in the biotechnology and pharmaceutical sectors, currently serving as the Chief Scientific Officer, Board Director, and Founding CEO of RAGE Biotech, which focuses on novel therapeutics for inflammatory diseases. Previous leadership roles include CEO of MycRx, a company developing cancer therapies, and CEO of Otifex Therapeutics, specializing in treatments for balance disorders. With expertise spanning various companies, including Athena Medicines, Aravax, and miReven, Christopher Wraight has a strong background in drug development and strategic advisory roles, supported by academic qualifications including a PhD in Biochemistry and an MBA in Technology Management.